As per MRFR analysis, the China Liquid Biopsy Market Size was estimated at 494.03 (USD Million) in 2023.The China Liquid Biopsy Market Industry is expected to grow from 546.0(USD Million) in 2024 to 1,641.0 (USD Million) by 2035. The China Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.522% during the forecast period (2025 - 2035)
China's liquid biopsy market is experiencing significant trends driven by rapid advancements in technology and increasing investment in healthcare research. The growing burden of cancer, which remains a leading cause of death in China, is pushing for more effective and less invasive diagnostic tools like liquid biopsies. The government's focus on enhancing cancer screening and early diagnosis is evident through various health initiatives and policies aimed at improving patient outcomes. This has led to a rising adoption of liquid biopsy techniques among healthcare professionals and institutions. Opportunities in the China liquid biopsy market are expanding as awareness of genetic testing and personalized medicine grows.With a large population and a rising incidence of cancer, there is a substantial demand for non-invasive diagnostic solutions.
Companies are increasingly investing in R to develop advanced technologies for circulating tumor DNA (ctDNA) analysis, which is a key area of exploration within the market. Collaborations between academic institutions and biotech firms are becoming more common, further driving innovation and product development. Recently, there has been a trend toward integrating artificial intelligence and machine learning in liquid biopsy analyses, improving the accuracy and efficiency of testing processes. Regulatory bodies in China are also streamlining approval processes for liquid biopsy tests, which supports quicker market access for new technologies.As healthcare systems evolve, the adoption of liquid biopsies is likely to increase, reflecting a shift towards more personalized and precise patient care. Overall, the trends indicate a growing recognition of the potential of liquid biopsy technologies in transforming cancer diagnostics in China.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Rising Incidence of Cancer in China
The increasing number of cancer cases in China is a significant driver for the China Liquid Biopsy Market industry. According to the National Cancer Center of China, about 4.57 million new cancer cases were reported in 2020, marking a 30% increase compared to 2015 figures. This alarming rise in cancer rates underscores the urgent need for advanced diagnostic technologies, including liquid biopsies, which are less invasive compared to traditional methods.The Chinese government is actively promoting early cancer detection programs, which further fuels the demand for innovative solutions, thereby contributing to the growth of the liquid biopsy market.
Technological Advancements in Diagnostic Methods
Technological innovation significantly enhances the capabilities of the China Liquid Biopsy Market industry. Major corporations such as Tencent and BGI Group are investing in research and development to improve liquid biopsy technologies, contributing to more accurate and sensitive detection of cancer biomarkers. According to the Ministry of Science and Technology of China, investment in biotechnology has surged by over 12% annually since 2018, fostering an environment that encourages rapid development of liquid biopsy methodologies.These advancements not only improve diagnosis but also expand the scope of liquid biopsies for cancer monitoring and treatment response evaluation.
Government Support and Regulatory Framework
The development of the China Liquid Biopsy Market is further driven by China's encouraging government policies. Policies designed to encourage the development of precision medicine and early diagnosis have been put in place, motivating firms to seek new ways to puncture the liquid biopsy industry. The State Council of China hopes to greatly advance in cancer control and prevention and is looking forward to greatly increasing the funding allocated to early detection programs.With such policies paving the way for better funding and support for liquid biopsy technologies, the market is poised for robust growth as more companies enter this promising sector.
Growing Public Awareness and Acceptance
Public awareness about the importance of early cancer detection is growing in China, creating a favorable environment for the China Liquid Biopsy Market industry. Education campaigns supported by health organizations and hospitals are playing a crucial role in informing the populace about the benefits of liquid biopsy tests over traditional tissue biopsies. As per reports from the Chinese Center for Disease Control and Prevention, there has been a 20% increase in awareness about liquid biopsy tests among patients seeking cancer screenings in the past three years.This growing acceptance is driving demand for liquid biopsy services, thus fostering market growth.
The China Liquid Biopsy Market is experiencing notable growth, driven by the advancement of diagnostic technologies and an increasing emphasis on non-invasive testing methods. Liquid biopsy, which involves analyzing bodily fluids like blood for cancer biomarkers, has emerged as a pivotal component in cancer management and early detection, enabling timely diagnosis and personalized treatment plans. Within this market, several types are recognized, including Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), and others, each playing an essential role in understanding tumor dynamics and patient-specific responses.
Circulating Tumor Cells represent a critical area as they provide insights into tumor progression by allowing clinicians to monitor metastasis and treatment efficacy. Their ability to be isolated and analyzed provides invaluable data for real-time decision-making in oncology. Circulating Tumor DNA, on the other hand, has gained significant traction due to its potential for offering genetic information about the tumor's mutations and alterations, which is vital for targeted therapies. The non-invasive nature of ctDNA testing adds to its appeal, making it an integral tool in precision medicine and biomarker research.
Extracellular Vesicles, which include exosomes, are significant carriers of molecular information, reflecting the tumor microenvironment and facilitating intercellular communication. Their analysis can provide insights into the tumor's molecular makeup and its biological activity, offering promising opportunities for developing new therapeutic strategies. Moreover, the segment categorized as 'Others' encompasses a broad range of emerging techniques and methodologies, which continue to evolve as research in liquid biopsies expands.
This diversification within the China Liquid Biopsy Market segmentation illustrates the dynamic nature of cancer diagnostics and the potential for improving patient outcomes through early detection and treatment personalization. Factors such as an aging population, rising cancer incidence, and a growing preference for non-invasive techniques are expected to significantly drive market developments. Furthermore, challenges like regulatory hurdles and the need for robust clinical validation remain prominent but also present opportunities for innovation and growth within the industry. The combination of these elements positions the China Liquid Biopsy Market as a critical frontier in oncology, contributing to advancements in medical science and improved healthcare delivery in the region.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China Liquid Biopsy Market is experiencing notable advancements, particularly within the Application segment, which includes key areas such as Cancer Therapeutic Application, Reproductive Health, and others. Cancer Therapeutic Applications play a critical role in early detection and personalized treatment, with liquid biopsies becoming integral in monitoring tumor progression and response to therapy. This segment is significant as it empowers healthcare providers to tailor treatments based on real-time insights into patients' conditions. Reproductive Health is gaining traction, focusing on prenatal testing and genetic screenings, essential for assessing risks and ensuring healthy pregnancies.This segment highlights the increasing awareness and demand for non-invasive testing methods among expectant parents in China.
Other applications within the Liquid Biopsy Market further explore various diagnostic purposes, showcasing the versatility and growing potential of liquid biopsies in diverse healthcare fields. The market is bolstered by technological advancements and an evolving regulatory framework in China, driving the adoption of liquid biopsy solutions and addressing the rising burden of cancer and reproductive health issues. These factors collectively underline the significance of the Application segment within the China Liquid Biopsy Market, positioning it for sustained growth and innovation.
The China Liquid Biopsy Market is evolving significantly, with a focus on various sample types, including blood, urine and others. Blood samples are particularly critical due to their ability to provide comprehensive genomic information, making them a popular choice for cancer diagnosis and monitoring. Urine samples, on the other hand, are gaining traction due to their non-invasive nature and ease of collection, which aligns well with patient preferences and regulatory compliance in China.
The growing incidence of cancer and the increasing demand for early detection methods are driving the relevance of these sample types in the liquid biopsy landscape.Furthermore, advancements in technology and analytical methods are enhancing the accuracy and reliability of liquid biopsy tests, thereby reinforcing their importance in clinical settings. As a result, the segments within the China Liquid Biopsy Market are poised to witness robust growth, contributing significantly to market dynamics and service offerings in precision medicine.
China Liquid Biopsy Market Key Players and Competitive Insights
The China Liquid Biopsy Market is witnessing a significant transformation propelled by innovations in molecular diagnostics and a growing emphasis on precision medicine. As healthcare systems aim to adopt less invasive and more accurate testing methodologies, liquid biopsy technologies have emerged as a prominent alternative to traditional tissue biopsies. This market is characterized by strategic collaborations, advancements in technology, and the establishment of regulatory frameworks to facilitate rapid growth. Competition in this landscape is driven not only by technological capabilities but also by partnerships between biopharmaceutical companies and research institutions, enhancing the scope and effectiveness of liquid biopsy applications in cancer diagnosis and monitoring.FudanZhangjiang BioPharmaceutical has carved a substantial niche in the China Liquid Biopsy Market, leveraging its strengths in research and development.
The company is known for its strong focus on developing innovative platforms for liquid biopsy solutions that cater specifically to cancer detection and personalized medicine. FudanZhangjiang BioPharmaceutical has been active in building partnerships with leading hospitals and research institutions in China, which bolsters its market presence and operational efficacy. By continuously refining its technologies and enhancing its product offerings, the company positions itself favorably against competitors, demonstrating a commitment to revolutionizing cancer diagnostics in the region.
Its specialized expertise and infrastructural investments play a crucial role in addressing the increasing demand for non-invasive cancer testing solutions across the Chinese healthcare system.Horizon Discovery has also established a solid footing in the China Liquid Biopsy Market, focusing on providing advanced molecular tools and services essential for precision medicine. The company emphasizes the development of key products related to gene editing and genomic analysis, which are critical in the context of liquid biopsy applications. Horizon Discovery has a strategic presence in the region through collaborations with local biotech firms and healthcare organizations aimed at advancing liquid biopsy technologies.
The company’s strengths lie in its innovative research capabilities and its comprehensive service offerings that amplify its market authority. Horizon Discovery has pursued growth through various mergers and acquisitions, enhancing its technological portfolio and expanding its reach within China. This approach not only enriches its product line but also solidifies its position as a key player in the .
Key Companies in the China Liquid Biopsy Market Include
China Liquid Biopsy Market Industry Developments
In recent developments within the China Liquid Biopsy Market, significant strides have been observed among key players such as FudanZhangjiang BioPharmaceutical and BGI. Notably, in October 2023, BGI announced advancements in its NGS-based liquid biopsy technologies, enhancing early cancer detection capabilities. In terms of market growth, the valuation of significant companies like GeneplusBeijing and Sysmex Corporation has surged, largely due to increased investments in oncology diagnostics and growing adoption of liquid biopsy technologies across healthcare facilities in China.
Furthermore, mergers and acquisitions amid this competitive landscape have gained momentum, with GeneCast recently acquiring Nanjing Geneseeq Technology to expand its product offerings, an event reported in July 2023. Major happenings from earlier years include the establishment of a comprehensive regulatory framework by the Chinese National Medical Products Administration in April 2022, which further stimulated market growth by promoting innovations in liquid biopsy testing. As the demand for non-invasive diagnostic methods continues to escalate, companies like Guangzhou Jusda Healthcare Technology and MediSapiens are positioning themselves strategically to capture new market opportunities, making the China liquid biopsy segment vibrant and rapidly evolving.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 494.03(USD Million) |
| MARKET SIZE 2024 | 546.0(USD Million) |
| MARKET SIZE 2035 | 1641.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.522% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | FudanZhangjiang BioPharmaceutical, Horizon Discovery, China Medical System Holdings, MediSapiens, Sysmex Corporation, GeneplusBeijing, Shenzhen Genomics, GeneCast, Wuxi NextCode, Zhejiang 3H Medical Science, BGI, Guangzhou Jusda Healthcare Technology, Nanjing Geneseeq Technology, Adicon, Ribomed Biotechnologies |
| SEGMENTS COVERED | Types, Application, Sample |
| KEY MARKET OPPORTUNITIES | Rising cancer prevalence, Government support for diagnostics, Increasing demand for non-invasive solutions, advancements in genomic technologies, Expanding personalized medicine initiatives |
| KEY MARKET DYNAMICS | Rising cancer prevalence, Advancements in technology, Growing awareness of early diagnosis, Supportive government regulations, Increasing R&D investments |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The China Liquid Biopsy Market is expected to be valued at approximately 546.0 USD Million in 2024.
By 2035, the market is projected to reach about 1641.0 USD Million.
The market is anticipated to grow at a CAGR of 10.522% during the forecast period of 2025 to 2035.
Circulating Tumor DNA is projected to have the largest market share valued at 203.0 USD Million in 2024.
The Circulating Tumor Cells segment is expected to be valued at 446.5 USD Million in 2035.
Major players include FudanZhangjiang BioPharmaceutical, Horizon Discovery, and BGI among others.
The Extracellular Vesicles segment is expected to be valued at 122.0 USD Million in 2024.
Emerging trends in personalized medicine and non-invasive diagnostic methods present growth opportunities.
The Others segment is projected to be valued at 200.0 USD Million by 2035.
Regulatory hurdles and the need for clinical validation may pose challenges for market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
